• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Is Zoetis Inc. (NYSE: ZTS) Overvalued? Or Is It Worth Buying Now?

    1/7/25 4:15:00 PM ET
    $LKQ
    $ZTS
    Motor Vehicles
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LKQ alert in real time by email

    TROY, Mich., Jan. 7, 2025 /PRNewswire/ -- Zoetis's recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine considers Zoetis (NYSE:ZTS) as worthy of further study and has named Zoetis its "Stock to Study" for the March 2025 issue for investors' informational and educational use.

    The fundamental data is eye-opening; investors can view Zoetis's sales, earnings, pre-tax profit, return on equity, and more all on one page, courtesy of the National Association of Investors, at:  https://ssg.betterinvesting.org/trial/ssgplus/?ticker=ZTS.

    A full report on Zoetis will appear in the March 2025 issue of BetterInvesting Magazine. 

    The same issue of BetterInvesting Magazine will also include a fundamental review of LKQ Corp. (NASDAQ:LKQ) which the independent Editorial Advisory and Securities Review Committee believes is worthy of further study from an undervalued perspective. 

    Committee members are Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip Keating, CFA; Walter J. Kirchberger, CFA; Anne Nichols, CFA; and Dan Rutter, CFA.

    Securities mentioned are for study and presented for educational purposes only. They are not to be considered as endorsed or recommended for purchase by NAIC/BetterInvesting. Investors should conduct their own review and analysis of any company of interest using the Stock Selection Guide before making an investment decision.

    About BetterInvesting:

    BetterInvesting™, a national 501(c)(3) nonprofit, investment education organization, has been empowering everyday Americans since 1951. Also known as the National Association of Investors™ (NAIC®), we have helped more than 5 million people from all walks of life learn how to improve their financial future. BetterInvesting provides unbiased, in-depth investing education and powerful online stock analysis tools to create successful lifelong investors. BetterInvesting staff, along with a dedicated community of volunteers across America, teach the organization's principles and time-tested methodology to individuals and investment clubs. For more information about BetterInvesting, please visit www.betterinvesting.org

    Follow us on LinkedIn, Instagram and Facebook.

    Contact: 877-275-6242

    Cision View original content:https://www.prnewswire.com/news-releases/is-zoetis-inc-nyse-zts-overvalued-or-is-it-worth-buying-now-302344973.html

    SOURCE National Association of Investors/BetterInvesting

    Get the next $LKQ alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LKQ
    $ZTS

    CompanyDatePrice TargetRatingAnalyst
    Zoetis Inc.
    $ZTS
    6/18/2025$160.00Buy → Hold
    Stifel
    Zoetis Inc.
    $ZTS
    12/2/2024$215.00Outperform
    Leerink Partners
    Zoetis Inc.
    $ZTS
    7/25/2024$220.00Buy
    BTIG Research
    Zoetis Inc.
    $ZTS
    1/12/2024$195.00 → $215.00Buy
    Stifel
    Zoetis Inc.
    $ZTS
    12/19/2023$230.00Buy
    Jefferies
    Zoetis Inc.
    $ZTS
    12/7/2023$237.00Outperform
    Exane BNP Paribas
    Zoetis Inc.
    $ZTS
    9/6/2023$230.00Buy
    HSBC Securities
    LKQ Corporation
    $LKQ
    7/13/2022$68.00Buy
    MKM Partners
    More analyst ratings

    $LKQ
    $ZTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Jude Justin L bought $100,178 worth of shares (2,708 units at $36.99), increasing direct ownership by 0.97% to 280,777 units (SEC Form 4)

      4 - LKQ CORP (0001065696) (Issuer)

      4/25/25 3:49:19 PM ET
      $LKQ
      Motor Vehicles
      Consumer Discretionary
    • SVP - General Counsel Mckay Matthew J bought $99,375 worth of shares (2,500 units at $39.75), increasing direct ownership by 3% to 94,670 units (SEC Form 4)

      4 - LKQ CORP (0001065696) (Issuer)

      7/29/24 2:46:58 PM ET
      $LKQ
      Motor Vehicles
      Consumer Discretionary
    • SVP and CFO Galloway Rick bought $99,700 worth of shares (2,500 units at $39.88), increasing direct ownership by 4% to 58,126 units (SEC Form 4)

      4 - LKQ CORP (0001065696) (Issuer)

      7/29/24 2:46:46 PM ET
      $LKQ
      Motor Vehicles
      Consumer Discretionary

    $LKQ
    $ZTS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zoetis to Host Webcast and Conference Call on Second Quarter 2025 Financial Results

      Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, August 5, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2025 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay of the webcast will be made available on August 5, 2025. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpos

      7/1/25 8:30:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LKQ Corporation to Release Second Quarter 2025 Results on Thursday, July 24, 2025

      ANTIOCH, Tenn., June 26, 2025 (GLOBE NEWSWIRE) -- LKQ Corporation (NASDAQ:LKQ) will release its second quarter 2025 financial results on Thursday, July 24, 2025. Conference Call Details LKQ will host a conference call and webcast on July 24, 2025 at 8:00 a.m. Eastern Time (7:00 a.m. Central Time) with members of senior management to discuss the Company's results. To access the investor conference call, please dial (833) 470-1428. International access to the call may be obtained by dialing (404) 975-4839. The investor conference call will require you to enter conference ID: 409932. Webcast and Presentation Details The audio webcast and accompanying slide presentation can be acce

      6/26/25 10:00:00 AM ET
      $LKQ
      Motor Vehicles
      Consumer Discretionary
    • LKQ Corporation and SYNETIQ, an IAA Company Announce Strategic European Joint Venture

      ANTIOCH, Tenn., June 24, 2025 (GLOBE NEWSWIRE) -- LKQ Corporation (NASDAQ:LKQ), today announced that LKQ Europe has entered into a joint venture with SYNETIQ Ltd., an IAA company. LKQ Europe is the leading distributor of automotive aftermarket parts for cars, commercial vans, and industrial vehicles in Europe. SYNETIQ is one of the UK's leading vehicle salvage, dismantling and recycling companies. LKQ SYNETIQ, the newly named joint venture, will combine LKQ's unrivalled distribution reach and data-driven logistics network with SYNETIQ's market-leading dismantling, reuse and remanufacturing expertise—approximately 27,000 vehicles dismantled annually across four UK sites in 2024. The joint

      6/24/25 8:00:00 AM ET
      $LKQ
      Motor Vehicles
      Consumer Discretionary

    $LKQ
    $ZTS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • January 13, 2022 - FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

      For Immediate Release: January 13, 2022 Today, the U.S. Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats and the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species.  Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody (a type o

      1/13/22 10:26:13 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LKQ
    $ZTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Zoetis downgraded by Stifel with a new price target

      Stifel downgraded Zoetis from Buy to Hold and set a new price target of $160.00

      6/18/25 7:45:54 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Zoetis with a new price target

      Leerink Partners initiated coverage of Zoetis with a rating of Outperform and set a new price target of $215.00

      12/2/24 7:04:18 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Zoetis with a new price target

      BTIG Research initiated coverage of Zoetis with a rating of Buy and set a new price target of $220.00

      7/25/24 6:48:19 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LKQ
    $ZTS
    SEC Filings

    See more
    • SEC Form 11-K filed by Zoetis Inc.

      11-K - Zoetis Inc. (0001555280) (Filer)

      6/23/25 4:44:01 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SD filed by Zoetis Inc.

      SD - Zoetis Inc. (0001555280) (Filer)

      6/2/25 4:04:30 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SD filed by LKQ Corporation

      SD - LKQ CORP (0001065696) (Filer)

      5/28/25 4:07:19 PM ET
      $LKQ
      Motor Vehicles
      Consumer Discretionary

    $LKQ
    $ZTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Vice President Lagano Roxanne sold $110,840 worth of shares (652 units at $170.00), decreasing direct ownership by 4% to 15,129 units (SEC Form 4)

      4 - Zoetis Inc. (0001555280) (Issuer)

      6/4/25 4:31:39 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Scully Robert W converted options into 17,535 shares, increasing direct ownership by 443% to 21,489 units (SEC Form 4)

      4 - Zoetis Inc. (0001555280) (Issuer)

      5/23/25 12:14:50 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Stetter Mark

      4 - Zoetis Inc. (0001555280) (Issuer)

      5/22/25 6:32:13 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LKQ
    $ZTS
    Financials

    Live finance-specific insights

    See more
    • Zoetis to Host Webcast and Conference Call on Second Quarter 2025 Financial Results

      Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, August 5, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2025 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay of the webcast will be made available on August 5, 2025. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpos

      7/1/25 8:30:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LKQ Corporation to Release Second Quarter 2025 Results on Thursday, July 24, 2025

      ANTIOCH, Tenn., June 26, 2025 (GLOBE NEWSWIRE) -- LKQ Corporation (NASDAQ:LKQ) will release its second quarter 2025 financial results on Thursday, July 24, 2025. Conference Call Details LKQ will host a conference call and webcast on July 24, 2025 at 8:00 a.m. Eastern Time (7:00 a.m. Central Time) with members of senior management to discuss the Company's results. To access the investor conference call, please dial (833) 470-1428. International access to the call may be obtained by dialing (404) 975-4839. The investor conference call will require you to enter conference ID: 409932. Webcast and Presentation Details The audio webcast and accompanying slide presentation can be acce

      6/26/25 10:00:00 AM ET
      $LKQ
      Motor Vehicles
      Consumer Discretionary
    • Zoetis Declares Third Quarter 2025 Dividend

      The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the third quarter of 2025. The dividend will be paid on Wednesday, September 3, 2025, to all holders of record of the Company's common stock as of the close of business on Friday, July 18, 2025. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The c

      5/21/25 4:15:00 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LKQ
    $ZTS
    Leadership Updates

    Live Leadership Updates

    See more
    • Dr. Mark Stetter Elected to Zoetis Board of Directors

      Dean of the University of California, Davis School of Veterinary Medicine brings extensive and valuable experience in animal health to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company's annual shareholder meeting on May 21, 2025. Dr. Stetter brings extensive experience in veterinary medicine and animal health, including as Dean of the University of California, Davis School of Veterinary Medicine, to the Zoetis Board. His career in animal health includes pets, livestock, exotic animals, research and wildlife. He will serve on the Board's Quality and Innovation Committee. "Dr. Stetter brings invaluab

      5/22/25 4:15:00 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LKQ Corporation Appoints Sue Gove and Michael Powell to its Board

      Enters into Cooperation Agreement with Ancora and Engine Capital Forms Finance Committee ANTIOCH, Tenn., Feb. 06, 2025 (GLOBE NEWSWIRE) -- LKQ Corporation (NASDAQ:LKQ) ("LKQ" or the "Company") today announced the appointment of two new independent directors, Sue Gove and Michael Powell, to its Board of Directors (the "Board"), effective immediately, and the formation of a Finance Committee of the Board. In connection with these enhancements, the Company has entered into a Cooperation Agreement (the "Agreement") with Ancora Catalyst Institutional, LP, Engine Capital, LP and certain of their affiliates following constructive engagement. Ms. Gove currently serves as Founder and President o

      2/6/25 8:00:00 AM ET
      $LKQ
      Motor Vehicles
      Consumer Discretionary
    • LKQ Corporation Continues Board Refreshment with the Appointment of James S. Metcalf

      ANTIOCH, Tenn., Dec. 11, 2024 (GLOBE NEWSWIRE) -- LKQ Corporation (NASDAQ:LKQ) ("LKQ" or the "Company") today announced that it has appointed James S. Metcalf to its Board of Directors (the "Board") as a new independent director effective December 11, 2024, as part of the Board's ongoing refreshment process. The Company also announced that Dominick Zarcone has decided not to stand for re-election and will retire from the Board when his term expires in connection with the Company's 2025 Annual Meeting. Following the 2025 Annual Meeting, the Board will consist of ten directors, nine of whom are independent. "Our Board is committed to active and ongoing refreshment to ensure it has the right

      12/11/24 8:00:00 AM ET
      $FERG
      $LKQ
      $ROCK
      Miscellaneous
      Motor Vehicles
      Consumer Discretionary
      Steel/Iron Ore

    $LKQ
    $ZTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by LKQ Corporation

      SC 13G - LKQ CORP (0001065696) (Subject)

      11/7/24 4:30:56 PM ET
      $LKQ
      Motor Vehicles
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

      SC 13G/A - Zoetis Inc. (0001555280) (Subject)

      2/13/24 5:17:36 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by LKQ Corporation (Amendment)

      SC 13G/A - LKQ CORP (0001065696) (Subject)

      2/13/24 5:08:05 PM ET
      $LKQ
      Motor Vehicles
      Consumer Discretionary